Figure 6 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas

The brigatinib + INK128 combination effectively shrank intracranial AG-NF2-Men-Luc2 meningioma xenografts. A, Mice with established meningioma xenografts were treated with vehicle, brigatinib, INK128, or the brigatinib + INK128 combination by oral gavage, and tumor growth was monitored by BLI. The relative tumor-emitted BL signals were quantified and denoted as % of total flux after treatment relative to the total flux prior to treatment designated as one (100%). B, To assess potential tumor regrowth, we stopped treating mice in the INK128 or combination treatment group for 8 weeks and continued monitoring tumor growth by BLI for another 6 weeks. To examine the effects of re-treatment, we resumed treatment and continued BLI monitoring for 6 more weeks. The data are shown as the mean ± SE.